Neutral Endopeptidase for Early Detection of Acute Kidney Injury After Cardiac Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-10-30

Study Completion Date

2019-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators want to investigate if the urinary biomarker neprilysin can identify cardiac surgical patients suffering from postoperative AKI within 24 hours.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Urine and Serum Biomarkers for Early Detection of Acute Kidney Injury

NCT01531985

Congenital Heart Disease

COMPLETED

Biomarkers of Acute Kidney Injury in Cardiac Surgery

NCT03830450

Acute Kidney Injury (Nontraumatic)

UNKNOWN

Examining New Diagnostic Tests for Acute Kidney Injury After Heart Surgery

NCT00774137

Kidney Failure, Acute Renal Insufficiency

COMPLETED

A NEW WAY TO DETECT ACUTE KIDNEY INJURY

NCT07198906

Acute Renal Failure

NOT_YET_RECRUITING

Prevention of Acute Kidney Injury in Cardiac Surgery Patients

NCT00921518

Kidney Injury

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Acute kidney injury (AKI) is a common complication following cardiac surgery and significantly increases morbidity, duration of hospital stay, and mortality. The diagnosis of AKI relies on changes in serum creatinine (SCr) from a baseline value or decreases in urine output. Nevertheless changes of SCr to diagnose AKI are only reliable after a minimum of 48 hours.

Neutral endopeptidase, also called neprilysin (NEP) represents a single-pass membrane glycoprotein with zinc-dependent endopeptidase activity and a short cytosolic tail and is found in epithelia, fibroblasts, and neutrophils and in soluble form in the circulation, urine, and cerebrospinal fluid. Beside the focus of interest in cardiovascular medicine for its role in heart failure, where the inhibition of NEP by the administration of sacubitril/valsartan may achieve an improvement in patients with chronic heart failure and reduced ejection fraction, there is also thought to be a link to renal damage.

NEP is expressed in the brush border of proximal tubular cells, which is first shed in renal damage and therefore it is a marker for tubular damage when it is measurable in urine In this study the investigators want to investigate if NEP is a marker for earlier detection of AKI after elective cardiac surgery compared to the currently recommended Kidney Disease - Improved Global Outcomes (KDIGO) guidelines for acute kidney injury. Also, the investigators want to investigate at predefined time points the occurrence and the progression of tubular damage during cardio-pulmonary bypass (CPB) in a closed-meshed NEP detection.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Kidney Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AKI

patients with postoperative AKI defined by KDIGO

Cardiac surgery

Intervention Type PROCEDURE

no AKI

patients without postoperative AKI defined by KDIGO

Cardiac surgery

Intervention Type PROCEDURE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cardiac surgery

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Patients undergoing an elective cardiac surgical intervention

Exclusion Criteria

* Emergency procedures
* Heart transplantation
* Elective left ventricular assist device (LVAD) implantation
* Pulmonary thrombendarterectomy
* Declined informed consent
* Age \< 18 years
* Pregnant woman
* Preoperative renal replacement therapy (RRT)
* Receiving medication containing sacubitril

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No